G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients : evaluation of its pathogenicity and inferences on its genealogical historyANAGNOSTOPOULOS, Theodore; PERTESI, Maroulio; FOUNTZILAS, George et al.Breast cancer research and treatment. 2008, Vol 110, Num 2, pp 377-385, issn 0167-6806, 9 p.Article

Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancerANTILL, Yoland; REYNOLDS, John; YOUNG, Mary-Anne et al.European journal of cancer (1990). 2006, Vol 42, Num 5, pp 621-628, issn 0959-8049, 8 p.Article

A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer riskWAKEFIELD, Claire E; MEISER, Bettina; TUCKER, Kathy et al.Breast cancer research and treatment. 2008, Vol 107, Num 2, pp 289-301, issn 0167-6806, 13 p.Article

Molecular pathologic analysis enhances the diagnosis and management of Muir-Torre syndrome and gives insight into its underlying molecular pathogenesisSOUTHEY, Melissa C; YOUNG, Mary-Anne; VENTER, Deon J et al.The American journal of surgical pathology. 2001, Vol 25, Num 7, pp 936-941, issn 0147-5185Article

A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutationsESPLEN, Mary Jane; HUNTER, Jon; KIEFFER, Stephanie et al.Cancer. 2004, Vol 101, Num 10, pp 2327-2340, issn 0008-543X, 14 p.Article

Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications?KEOGH, Louise A; VAN VLIET, Christine M; ROSENTHAL, Doreen A et al.Medical journal of Australia. 2009, Vol 191, Num 5, pp 255-258, issn 0025-729X, 4 p.Article